J.M. Dutton & Associates Announces Investment Opinion: Nymox Buy Rating Maintained by Dutton...

Business Editors

NOTE TO EDITORS: The following is an investment opinion issued

by J.M. Dutton & Associates

EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Oct. 6, 2003

J.M. Dutton & Associates continues coverage of Nymox, Inc. (Nasdaq:NYMX), maintaining

Nymox's product pipeline moves forward in its primary areas of therapeutic interest, Alzheimer's disease (AD) and anti-infectives. In AD, Nymox is pursuing a three-pronged strategy: prevention, detection and diagnosis, and treatment; it remains well positioned to address these needs, with its current technology in AD-associated proteins and its patent for the use of statins as preventative and therapeutic measures against AD. It presented data at the fourth Manhattan Alzheimer's Disease Conference held in May in NYC. Also, data from a completed four-month European study employing Nymox's NicAlert(TM) one-step urine test for tobacco exposure as an adjunct to nicotine replacement therapy was presented at the twelfth World Congress on Tobacco or Health in Helsinki. Nymox's anti-infectives program saw the announcement of a research collaboration with Health Canada's Laboratory for Foodborne Zoonoses focusing on the development of novel animal and related treatments for E. coli 0157:H7.

About Dutton & Associates

Dutton & Associates is one of the largest independent investment research firms in the U.S., with over 60 companies under coverage. Its 21 analysts, primarily CFAs, have expertise in many industries. Dutton & Associates provides continuing analyst coverage of enrolled companies, and its institutional-quality research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $28,000 prepaid before commencement of our research activities. We received $25,000 from the Company for coverage for the year, and do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.